Fresenius maps its strategy in hospital and care, shares in the DAX health sector focus

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-26, 11:16.

Fresenius (DE0005785604) remains a key healthcare name in the DAX as the group continues to refine its portfolio around hospital operations and infusion therapies. The focus is on the long-term strategy after the spin-off of Fresenius Medical Care and the restructuring program dubbed “Fresenius Focus”, as highlighted in the company’s recent strategy presentations and annual report. Fresenius annual report 2024

What Fresenius reports on its strategy

According to the 2024 annual report, Fresenius targets a simplified structure with two core operating segments: Fresenius Kabi for biopharma, nutrition and medical technologies, and Fresenius Helios for acute care hospitals and rehabilitation clinics. Fresenius annual report 2024 The company describes itself as a globally active healthcare group with a focus on therapies for chronically and critically ill patients.

Under the “Fresenius Focus” program, management aims to sharpen capital allocation and reduce complexity, including the deconsolidation of Fresenius Medical Care which is now treated as an investment at equity. Reuters coverage of Fresenius Focus strategy The group’s financial targets emphasize improving margins and cash conversion in both Kabi and Helios over the medium term.

Operations at Helios and Kabi in focus

Fresenius Helios operates hospitals in Germany and Spain, including the Quirónsalud network, making the group one of the largest private hospital operators in Europe. Fresenius Helios business overview The segment benefits from stable demand for inpatient care and an aging population, but also faces cost pressure from personnel and regulation.

Fresenius Kabi supplies clinical nutrition, generic IV drugs and infusion technologies, with a growing biopharmaceutical portfolio including biosimilars in oncology and autoimmune diseases. Fresenius Kabi facts and figures Management highlights the US and European markets as key growth regions, while also expanding manufacturing in Asia to improve cost efficiency.

How Fresenius makes its money

Fresenius generates most of its revenue from hospital services at Helios and from clinical nutrition, IV generics and medical devices at Kabi, complemented by its remaining stake in Fresenius Medical Care. One prominent product segment is parenteral nutrition solutions used in hospitals for patients who cannot eat normally.

Where the Fresenius shares trade

The Fresenius shares (DE0005785604) trade on Xetra, where they recently changed hands at around 39.8 euros in the DAX healthcare segment, based on data from finanzen.net and Deutsche Börse price feeds. Fresenius quote overview on finanzen100

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on publicly available sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research.